This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
DS Baldwin , KI Ajel , M Garner (2010). Pharmacological treatment of generalized anxiety disorder. Current Top Behavioral Neuroscience 2, 453–467.
M Bergstrom , R Hargreaves , D Burns , M Goldberg , (2004). Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant. Biological Psychiatry 55, 1007–1012.
R Carson , M Channing , R Blasberg , B Dunn , (1993). Comparison of bolus and infusion methods for receptor quantitation: application to [18F]cyclofoxy and positron emission tomography. Journal of Cerebral Blood Flow and Metabolism 13, 24–42.
J Culman , T Unger (1995). Central tachykinins: mediators of defense reaction and stress reactions. Canadian Journal of Physiology and Pharmacology 73, 885–891.
JR Davidson (2009). First-line pharmacotherapy approaches for generalized anxiety disorder. Journal of Clinical Psychiatry 70(Suppl. 2), 25–31.
K Ebner , SB Sartori , N Singewald (2009). Tachykinin receptors as therapeutic targets in stress-related disorders. Current Pharmaceutical Design 15, 1647–1674.
R Frank , R Hargreaves (2003). Clinical biomarkers in drug discovery and development. Nature Reviews in Drug Discovery 2, 566–580.
T Furmark , L Appel , A Michelgård , K Wahlstedt , (2005). Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. Biological Psychiatry 58, 132–142.
M Gail , R Simon (1985). Testing for qualitative interaction between effects and patient subsets. Biometrics 41, 361–372.
M Hamilton (1959). The assessment of anxiety states by rating. British Journal of Medical Psychology 32, 50–55.
M Hamilton (1960). A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry 23, 56–62.
R Hargreaves (2008). The role of molecular imaging in drug discovery and development. Clinical Pharmacology and Therapeutics 83, 1–5.
PJ Hesketh , SM Grunberg , J Herrstedt , R de Wit , (2006). Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response. Support Care Cancer 14, 354–360.
J Hietala , MJ Nyman , O Eskola , A Laakso , (2005). Visualization and quantification of neurokinin-1 (NK1) receptors in the human brain. Moleular Imaging and Biology 7, 262–272.
M Keller , S Montgomery , W Ball , M Morrison , (2006). Lack of efficacy of the substance P (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biological Psychiatry 59, 216–223.
M Kramer , A Winokur , J Kelsey , S Preskorn , (2004). Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology 29, 385–392.
MS Kramer , N Cutler , J Feighner , R Shrivastava , (1998). Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 281, 1640–1645.
A Lammertsma , S Hume (1996). Simplified reference tissue model for PET receptor studies. NeuroImage 4, 153–158.
SJ Mathew , M Vythilingam , JW Murrough , CA Zarate , (2011). A selective neurokinin-1 receptor antagonist in chronic PTSD: a randomized,double-blind, placebo-controlled, proof-of-concept trial. European Neuropsychopharmacoogy 21, 221–229.
A Raskin , J Schulterbrandt , N Reatig , JJ McKeon (1969). Replication of factors of psychopathology in interview, ward behavior and self-report ratings of hospitalized depressives. Journal of Nervous and Mental Disease 148, 87–98.
O Solin , O Eskola , TG Hamill , J Bergman , (2004). Synthesis and characterization of a potent, selective, radiolabeled substance-P antagonist for NK1 receptor quantitation: ([18F]SPA-RQ). Molecular Imaging and Biology 6, 373–384.
FD Tattersall , W Rycroft , M Cumberbatch , G Mason , (2000). The novel NK1 receptor antagonist MK-0869(L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets. Neuropharmacology 39, 652–663.
J Tauscher , W Kielbasa , S Iyengar , F Vandenhende , (2010). Development of the 2nd generation neurokinin-1 receptor antagonist LY686017 for social anxiety disorder. European Neuropsychopharmacology 20, 80–87.
RB Weisberg (2009). Overview of generalized anxiety disorder: epidemiology,presentation, and course. Journal of Clinical Psychiatry 70 (Suppl. 2), 4–9.
AS Zigmond , RP Snaith (1983).The hospital anxiety and depression scale. Acta Psychiatrica Scandinavica 67, 361–370.